StoneSmart
In this video, Juan Calle, MD, of Cleveland Clinic, explains what he would tell a young urologist who wants to become an expert in stone prevention and minimizing recurrence.
Related Articles
Survey: New NMIBC treatments face slow uptake
Results of an exclusive Urology Times survey point to urologists preferring intravesical chemotherapy for treating BCG-unresponsive NMIBC.
Considerations for pre-procedure urinalysis, periprocedural antibiotics for onabotA
Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.
Leva System adds Mayo Clinic overactive bladder content
Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.
FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
TMT for bladder cancer: Balancing cost and quality of life
According to Daniel D. Joyce, MD, MS, policy initiatives should focus on improving the value and efficiency of radiation.
Justin Dubin, MD, on the use of AI in the male infertility space
Justin M. Dubin, MD, outlines the current ways that artificial intelligence is being used in the male infertility space.
UK’s MHRA approves nogapendekin alfa inbakicept plus BCG in NMIBC
According to the company, the MHRA approval represents the first marketing approval outside the US for NAI.
Anne Schuckman, MD, outlines current challenges in NMIBC care
Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.
Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC
Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.
FDA and EMA authorize phase 3 trial of masitinib for mCRPC
For the trial, a biomarker will be utilized to aid in patient selection for the treatment.